MediWound Granted U.S. Patent for MWPC003 for the Treatment of Connective Tissue Diseases
December 20 2016 - 07:00AM
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical
company bringing innovative therapies to address unmet needs in
severe burn and wound management, announces that the United States
Patent and Trademark Office (USPTO) has issued patent Number
9,511,126 with claims related to the Company’s proprietary
injectable bromelain solution, MWPC003, for enzymatic treatment of
connective tissue diseases.
The new patent, titled “Proteolytic Extract from
Bromelain for the Treatment of Connective Tissue Disorders,”
provides broad protection for MWPC003 in the treatment of a variety
of connective tissue diseases, such as Dupuytren’s contracture,
Peyronie’s disease and scar treatment, among others.
MWPC003 is an investigational sterile injectable
solution containing a mixture of the same pharmaceutical-grade
proteolytic enzymes used in MediWound’s NexoBrid®, which is
approved in Europe and other geographies for burn
debridement.
“We are particularly encouraged by the expanding
role of our proprietary proteolytic enzymes as a treatment for a
variety of connective tissue disorders. This U.S. patent
further bolters our intellectual property position and provides us
with additional opportunities to build upon and/or monetize this
core asset,” noted Gal Cohen, President and Chief Executive Officer
of MediWound.
“Minimally invasive treatments have advantages
over traditional surgical methods and are in line with the general
medical trend of less invasiveness and increased convenience. The
scientific rationale for MWPC003 to treat connective tissue
disorders is based on its proteolytic properties, which allow it to
dissolve the pathological contracture tissue even when using very
low doses, and the potential of the reported
anti-inflammatory/immunomodulatory activity of bromelain to reduce
the high recurrence rate. We are encouraged by the potential
for MWPC003 as a therapeutic for connective tissue disorders and
look forward to filing an Investigational New Drug (IND)
application for MWPC003 for the treatment of connective tissue
disorders and to embarking on a clinical development program for
this exciting opportunity,” added Mr. Cohen.
About MediWound Ltd.
MediWound is a fully-integrated
biopharmaceutical company focused on developing, manufacturing and
commercializing novel therapeutics based on its patented
proteolytic enzyme technology to address unmet needs in the fields
of severe burns, chronic and other hard-to-heal wounds. MediWound’s
first innovative biopharmaceutical product, NexoBrid, received
marketing authorization from the European Medicines Agency as well
as the Israeli and Argentinian Ministries of Health, for removal of
dead or damaged tissue, known as eschar, in adults with deep
partial and full-thickness thermal burns and was launched in Europe
and Israel, with plans for a launch in Argentina.
NexoBrid represents a new paradigm in burn care management,
and clinical trials have demonstrated, with statistical
significance, its ability to non-surgically and rapidly remove the
eschar earlier and, without harming viable tissues.
MediWound's second innovative product, EscharEx®
is a topical biological drug being developed for debridement of
chronic and other hard-to-heal wounds and is complementary to the
large number of existing wound healing products, which require a
clean wound bed in order to heal the wound. EscharEx® contains the
same proteolytic enzyme technology as NexoBrid®, and benefits from
the wealth of existing development data on NexoBrid®. In two
Phase 2 studies, EscharEx® has demonstrated safety and efficacy in
the debridement of chronic and other hard-to-heal wounds, within a
few daily applications. For more information, please
visit www.mediwound.com.
Cautionary Note Regarding
Forward-Looking Statements
This release includes forward-looking statements
within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, Section 21E of the US Securities Exchange Act of
1934, as amended, and the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts, such as
statements regarding assumptions and results related to the
regulatory authorizations and launch dates. In some cases, you
can identify forward-looking statements by terminology such as
“believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “expect,” “predict,” “potential,” or the negative
of these terms or other similar expressions. Forward-looking
statements are based on MediWound’s current knowledge and its
present beliefs and expectations regarding possible future events
and are subject to risks, uncertainties and assumptions. Actual
results and the timing of events could differ materially from those
anticipated in these forward-looking statements as a result of
several factors. In particular, you should consider the risks
discussed under the heading “Risk Factors” in our annual report on
Form 20-F for the year ended December 31, 2015 and information
contained in other documents filed with or furnished to the
Securities and Exchange Commission. You should not rely upon
forward-looking statements as predictions of future events.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that
future results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or will occur. The forward-looking statements made herein
speak only as of the date of this announcement and MediWound
undertakes no obligation to update publicly such forward-looking
statements to reflect subsequent events or circumstances, except as
otherwise required by law.
Contacts:
Anne Marie FieldsSharon
Malka
Senior Vice PresidentChief Financial and Operations
Officer
LHAMediWound
212-838-3777ir@mediwound.co.il
afields@lhai.com
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Feb 2024 to Mar 2024
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Mar 2023 to Mar 2024